Comparative Pharmacology
Head-to-head clinical analysis: LOTRIMIN versus MENTAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOTRIMIN versus MENTAX.
LOTRIMIN vs MENTAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clotrimazole inhibits fungal cytochrome P450 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
Inhibits fungal squalene epoxidase, thereby blocking ergosterol biosynthesis and causing accumulation of squalene, leading to fungal cell death.
Clotrimazole 1% cream or solution applied topically to affected area twice daily for 2-4 weeks. For vaginal tablets: 100 mg intravaginally once daily for 7 days or 500 mg single dose. For troches: 10 mg troche dissolved slowly in mouth five times daily for 14 days.
Butenafine hydrochloride 1% cream: apply to affected area once daily for 2 weeks for tinea pedis; for tinea corporis and tinea cruris, apply once daily for 1 week.
None Documented
None Documented
Terminal elimination half-life is approximately 20-50 hours. Dose adjustments not required in renal impairment, but caution in hepatic impairment.
Terminal elimination half-life is approximately 5-6 hours; clinical significance: supports twice-daily dosing for topical antifungal therapy.
Approximately 70% of absorbed dose is excreted in feces as unchanged drug and metabolites; about 20% is excreted renally as metabolites with less than 1% unchanged. Biliary excretion is a minor route.
Primarily fecal (biliary) as unchanged drug and metabolites; renal excretion of metabolites accounts for less than 1% of the dose.
Category C
Category C
Topical Antifungal
Topical Antifungal